TD Cowen analyst Marc Frahm reiterated a Buy rating on Agios Pharma (NASDAQ: AGIO).The analyst commented, "Pending FDA approval, Agios ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE